Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCMNASDAQ:MORFNASDAQ:MRVINASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$13.86+4.8%$14.10$11.51▼$21.50$2.42B0.55100,672 shs61,240 shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsMRVIMaravai LifeSciences$2.37+7.2%$2.06$1.67▼$10.03$603.54M0.192.34 million shs1.71 million shsZLABZai Lab$31.31+3.4%$31.19$16.01▼$39.77$3.45B1.04872,673 shs646,170 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+4.76%+4.45%-8.58%-15.80%-25.72%MORFMorphic0.00%0.00%0.00%0.00%+89.34%MRVIMaravai LifeSciences+7.24%+3.04%+14.49%-26.40%-73.46%ZLABZai Lab+3.40%-3.66%-1.66%-9.61%+74.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED2.0112 of 5 stars3.02.00.00.02.20.01.9MORFMorphic0.9455 of 5 stars1.00.00.04.80.03.30.0MRVIMaravai LifeSciences4.2421 of 5 stars4.11.00.04.42.80.81.3ZLABZai Lab2.7267 of 5 stars3.43.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$19.0037.09% UpsideMORFMorphic 2.00Hold$57.000.02% UpsideMRVIMaravai LifeSciences 2.25Hold$6.64180.12% UpsideZLABZai Lab 2.75Moderate Buy$47.3751.28% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, MORF, MRVI, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MRVIMaravai LifeSciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/13/2025MRVIMaravai LifeSciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.003/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/25/2025MRVIMaravai LifeSciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.003/21/2025MRVIMaravai LifeSciencesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.003/21/2025MRVIMaravai LifeSciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $2.503/13/2025ZLABZai LabJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $51.003/7/2025ZLABZai LabScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/4/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025MRVIMaravai LifeSciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M3.83$0.57 per share24.51$4.27 per share3.25MORFMorphic$520K5,490.11N/AN/A$12.31 per share4.63MRVIMaravai LifeSciences$241.86M2.50$0.06 per share41.71$3.14 per share0.75ZLABZai Lab$418.33M8.26N/AN/A$8.05 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$100.78MN/A0.009.49N/AN/AN/AN/A6/18/2025 (Estimated)MORFMorphic-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/AMRVIMaravai LifeSciences-$119.03M-$1.14N/AN/AN/A-81.13%-6.61%-3.45%8/6/2025 (Estimated)ZLABZai Lab-$334.62M-$2.49N/AN/AN/A-76.14%-36.97%-27.10%8/5/2025 (Estimated)Latest ZLAB, MORF, MRVI, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AMORFMorphicN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.072.812.68MORFMorphicN/A24.1324.13MRVIMaravai LifeSciences0.8910.749.94ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%MORFMorphic94.25%MRVIMaravai LifeSciences50.25%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%MORFMorphic25.60%MRVIMaravai LifeSciences0.63%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableMORFMorphic10050.09 million37.27 millionOptionableMRVIMaravai LifeSciences610254.66 million250.94 millionOptionableZLABZai Lab1,950110.33 million94.24 millionOptionableZLAB, MORF, MRVI, and HCM HeadlinesRecent News About These CompaniesNorthern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 29 at 3:08 AM | marketbeat.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28 at 3:21 AM | seekingalpha.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28 at 3:00 AM | seekingalpha.comBNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 26, 2025 | marketbeat.comTwinbeech Capital LP Buys Shares of 27,039 Zai Lab Limited (NASDAQ:ZLAB)May 24, 2025 | marketbeat.comZai Lab Limited: Banking On Chinese Pharma GrowthMay 22, 2025 | seekingalpha.comWoodline Partners LP Has $46.09 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 270,136 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.com43,178 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Lazard Asset Management LLCMay 22, 2025 | marketbeat.comVestal Point Capital LP Invests $7.86 Million in Zai Lab Limited (NASDAQ:ZLAB)May 21, 2025 | marketbeat.comZai Lab gets FDA fast track status for lung cancer treatmentMay 19, 2025 | msn.comRTW Investments LP Takes Position in Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 233,103 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comLMR Partners LLP Makes New Investment in Zai Lab Limited (NASDAQ:ZLAB)May 17, 2025 | marketbeat.comMPM Bioimpact LLC Purchases Shares of 800,000 Zai Lab Limited (NASDAQ:ZLAB)May 16, 2025 | marketbeat.comYing Du Sells 46,389 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockMay 16, 2025 | insidertrades.comZai Lab FY2025 EPS Estimate Increased by Cantor FitzgeraldMay 16, 2025 | marketbeat.comJanus Henderson Group PLC Trims Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Sells 23,731 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 14, 2025 | marketbeat.comZai Lab Limited (ZLAB) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comThe Manufacturers Life Insurance Company Purchases 39,294 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLAB, MORF, MRVI, and HCM Company DescriptionsHUTCHMED NASDAQ:HCM$13.86 +0.63 (+4.76%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$13.86 +0.01 (+0.04%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Morphic NASDAQ:MORFMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Maravai LifeSciences NASDAQ:MRVI$2.37 +0.16 (+7.24%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.33 -0.04 (-1.69%) As of 05/29/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Zai Lab NASDAQ:ZLAB$31.31 +1.03 (+3.40%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$31.25 -0.06 (-0.19%) As of 05/29/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
